CLINICAL TRIAL: PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFEC

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项在HIV-1感染儿科患者中开展的新型蛋白酶抑制剂（BMS-232632）的多中心I/II期开放标签研究。 具有不同类型的治疗抵抗（不依从除外）的各种患者都有资格入组。 BMS-232632是一种C2-对称氮杂肽，结构上不同于许可的蛋白酶抑制剂，后者是肽模拟物。 迄今为止，成人中的主要毒性是高胆红素血症。 继续入组本研究。 结果尚未公布。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multicenter phase I/II open-label study of a novel protease inhibitor (BMS-232632) in HIV-1-infected pediatric patients. A wide variety of patients with varying types of therapeutic resistance (excepting noncompliance) are eligible for enrollment. BMS-232632 is a C2-symmetrical azapeptide structurally different from licensed protease inhibitors, which are peptidomimetic. The major toxicity to date in adults has been hyperbilirubinemia. Enrollment into this study continues. Results are not yet available.